text: Pfizer–BioNTech COVID jabs
  Pfizer–BioNTech COVID jabs (COVID-19 vaccine, RNA Vaccine) | |
  The Pfizer–BioNTech COVID-19 vaccine (tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech in collaboration with Pfizer. As of 30 March 2021, Pfizer and BioNTech aimed to manufacture about 2.5 billion doses in 2021.
  Pfizer Scientists: ‘Your [COVID] Antibodies Are Better Than The [Pfizer] Vaccination. / Project Veritas |
  - Full article: Reutlingen Pathological Institute
  - Full article: Reutlingen Pathological Institute
  The actual product is a trade secret, but a Pfizer injection contains maybe 14.400 trillion synthetic spike proteins wrapped in lipid nanoparticles. The nanoparticles might be able to carry 8 mRNA proteins each. The nanoparticles are made up of the widely used pharmaceutical ingredient polyethylene glycol (PEG). This is the first time they are used in an injection.
  The lipid shell plays a triple role. First, it protects the genetic material from degradation prior to cellular uptake. Second, the lipid shell, which also contains cholesterol, facilitates cellular uptake through fusion with the lipid membrane of the cell. And finally, it acts as an adjuvant.
  A 2019 study showed that small doses of PEG can lead to dramatic pathological immune activation. Animal studies has shown that it is responsible for both anaphylaxis and cardiovascular collapse, and injected PEG activates multiple allergic reactions in humans as well.
  In the clinical phase the RNA, was produced with completely different techniques to how it is being mass produced. During the clinical phase they only needed small volumes of vaccine, they were able to use very expensive techniques that delivered highly purified end products. Now that they have entered mass production, that is no longer possible, they have had to switch to lower-cost processes, e.g. using huge quantities of DNA that functions as the substrate to be able to produce the RNA in an in-vitro transcription reaction….
  Thorough evaluation means continue to collect data
  On 21 December 2020, following approval by the UK's MHRA and the US FDA, the European Medicines Agency (EMA) authorised the Pfizer BioNTech Covid-19 vaccine for the EU's nearly 448 million inhabitants. The EMA said the drug had demonstrated an efficacy of 95% and could be used in people aged 16 and over:
  - "Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, Emer Cooke. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the EU."
  On 26th of July 2021, the cybersecurity researcher Ehden Biber started to publish the contract Pfizer has with Brazil and Albania online, using the hashtag #PfizerLeak on Twitter. The exposure was quickly censored by Twitter.
  - As part of the sale, Pfizer made the governments explicitly acknowledge that long-term effects are still not known: “Purchaser further acknowledges that the long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are currently not known.”
  - Pfizer asked for additional indemnity from civil cases, meaning that the company would not be held liable for rare adverse effects or for its own acts of negligence, fraud or malice. This includes those linked to company practices – for example, if Pfizer sent the wrong vaccine or made errors during manufacturing.
  - The corporation asked the countries to put up sovereign assets, such as embassy buildings and military bases, as a guarantee against the cost of any future legal cases.
  In September 2021, Pfizer announced a COVID pill that is meant to be taken alongside the COVID vaccine. Pfizer is so confident that the pill will be swiftly approved and mandated by governments that it has already started manufacturing at scale at the same time as it started a phase 2/3 study.
  Pfizer CEO Albert Bourla instantly cashed in on the announcement, selling 60 percent of his Pfizer stock at $41.99, its highest level in more than a year.  The sale had been arranged in advance under a so-called Rule 10b5-1 trading plan, which allows corporate executives to make predetermined stock transactions in compliance with insider trading laws. Bourla adopted the trading plan in August of this year.
  Sally Susman, the company’s executive vice president and chief corporate affairs officer, dumped more than 43,000 shares to the tune of about $1.8 million.  The sale was allegedly made under a Rule 10b5-1 plan Susman adopted in November 2019.
  - "Covid: Pfizer-BioNTech vaccine approved for EU states"
  - https://senseofawareness.com/2021/07/29/pfizerleak-exposing-the-pfizer-manufacturing-and-supply-agreement-day-12/ saved at Archive.org saved at Archive.is